Overview

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer

Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of AD5-SGE-REIC/Dkk-3 in patients with localized prostate cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Momotaro-Gene Inc.
Collaborators:
Pacific-Link Consulting
The Pacific Link Consulting Co